MA26672A1 - Compositions pharmaceutiques contenant un inhibiteur de lipases gastro-intestinales, un (ou plusieurs) compose(s) supplémentaire(s) du groupe constitué par le chitosane, ses dérivés et ses sels, et des excipients auxiliaires - Google Patents
Compositions pharmaceutiques contenant un inhibiteur de lipases gastro-intestinales, un (ou plusieurs) compose(s) supplémentaire(s) du groupe constitué par le chitosane, ses dérivés et ses sels, et des excipients auxiliairesInfo
- Publication number
- MA26672A1 MA26672A1 MA25726A MA25726A MA26672A1 MA 26672 A1 MA26672 A1 MA 26672A1 MA 25726 A MA25726 A MA 25726A MA 25726 A MA25726 A MA 25726A MA 26672 A1 MA26672 A1 MA 26672A1
- Authority
- MA
- Morocco
- Prior art keywords
- chitosane
- derivatives
- salts
- group
- pharmaceutical compositions
- Prior art date
Links
- 229940086609 Lipase inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002496 gastric effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000546 pharmaceutical excipient Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98115310 | 1998-08-14 | ||
| EP99109430 | 1999-05-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA26672A1 true MA26672A1 (fr) | 2004-12-20 |
Family
ID=26149536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA25726A MA26672A1 (fr) | 1998-08-14 | 1999-08-11 | Compositions pharmaceutiques contenant un inhibiteur de lipases gastro-intestinales, un (ou plusieurs) compose(s) supplémentaire(s) du groupe constitué par le chitosane, ses dérivés et ses sels, et des excipients auxiliaires |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6030953A (fr) |
| EP (1) | EP1105123B1 (fr) |
| JP (1) | JP3761783B2 (fr) |
| KR (1) | KR20010079636A (fr) |
| CN (1) | CN1152680C (fr) |
| AR (1) | AR034691A1 (fr) |
| AT (1) | ATE263558T1 (fr) |
| AU (1) | AU759388B2 (fr) |
| BR (1) | BR9912979B1 (fr) |
| CA (1) | CA2340052C (fr) |
| CO (1) | CO5160286A1 (fr) |
| DE (1) | DE69916288T2 (fr) |
| DK (1) | DK1105123T3 (fr) |
| ES (1) | ES2217797T3 (fr) |
| MA (1) | MA26672A1 (fr) |
| PE (1) | PE20000954A1 (fr) |
| PT (1) | PT1105123E (fr) |
| TR (1) | TR200100472T2 (fr) |
| WO (1) | WO2000009123A1 (fr) |
| ZA (1) | ZA200100690B (fr) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6264937B1 (en) * | 1998-01-09 | 2001-07-24 | Geltex Pharmaceuticals, Inc. | Fat-binding polymers |
| US7048917B1 (en) | 1998-01-09 | 2006-05-23 | Genzyme Corporation | Fat-binding polymers |
| US6299868B1 (en) | 1999-07-14 | 2001-10-09 | Geltex Pharmaceuticals, Inc. | Fat-binding polymers |
| PT1105123E (pt) * | 1998-08-14 | 2004-08-31 | Hoffmann La Roche | Composicoes farmaceuticas contendo inibidores da lipase e quitosano |
| AU745697B2 (en) | 1998-09-08 | 2002-03-28 | Smithkline Beecham Corporation | Lipstatin derivative-soluble fiber tablets |
| AR025587A1 (es) | 1999-09-13 | 2002-12-04 | Hoffmann La Roche | Formulaciones en dispersion que contienen inhibidores de lipasa |
| AR025609A1 (es) * | 1999-09-13 | 2002-12-04 | Hoffmann La Roche | Formulaciones lipidas solidas |
| US6235305B1 (en) * | 1999-10-29 | 2001-05-22 | 2Pro Chemical | Essentially nonabsorbable lipase inhibitor derivatives, pharmaceutical compositions and methods of use therefor |
| EP1132389A1 (fr) | 2000-03-06 | 2001-09-12 | Vernalis Research Limited | Nouveaux dérivés de l'azaindole pour le traitement de l'obésité |
| FI20000780L (fi) * | 2000-04-03 | 2001-10-04 | Novasso Oy | Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi |
| EP1142572A1 (fr) * | 2000-04-04 | 2001-10-10 | Volker Dr. Helmstädter | Composés contenant de l'oxetanon destinés au traitement des maladies intestinales |
| JP4549486B2 (ja) * | 2000-04-26 | 2010-09-22 | アピ株式会社 | 抗肥満薬及びその製造方法 |
| ES2269441T3 (es) | 2000-06-27 | 2007-04-01 | F. Hoffmann-La Roche Ag | Metodo para la preparacion de una composicion. |
| KR100572785B1 (ko) | 2000-07-28 | 2006-04-19 | 에프. 호프만-라 로슈 아게 | 신규한 약학 조성물 |
| ATE293477T1 (de) | 2000-07-28 | 2005-05-15 | Hoffmann La Roche | Neue verwendung von lipase-inhibitoren |
| CA2417607C (fr) | 2000-08-09 | 2008-01-29 | Christine Feinle | Utilisation d'inhibiteurs de lipase |
| US6900226B2 (en) | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
| US6251421B1 (en) * | 2000-09-25 | 2001-06-26 | Sarfaraz K. Niazi | Pharmaceutical composition containing psyllium fiber and a lipase inhibitor |
| WO2002044152A1 (fr) | 2000-10-16 | 2002-06-06 | F. Hoffmann-La Roche Ag | Derives d'indoline et leur utilisation en tant que ligands de recepteur 5-ht2 |
| GB0030710D0 (en) | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
| BR0116605A (pt) | 2000-12-27 | 2003-09-30 | Hoffmann La Roche | Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono |
| GB0106177D0 (en) | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
| US20030072804A1 (en) * | 2001-03-19 | 2003-04-17 | The Procter & Gamble Company | Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body |
| US20030091610A1 (en) * | 2001-03-19 | 2003-05-15 | The Procter & Gamble Company | Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body |
| AU2002338896B2 (en) | 2001-05-21 | 2006-04-27 | F.Hoffman-La Roche Ag | Quinoline derivatives as ligands for the neuropeptide Y receptor |
| US7402405B2 (en) * | 2001-06-05 | 2008-07-22 | The Children's Hospital Of Philadelphia | Methods and kits for diagnosing a pancreatic-based fat malabsorption disorder |
| US20030027786A1 (en) | 2001-06-06 | 2003-02-06 | Karsten Maeder | Lipase inhibiting composition |
| US7049345B2 (en) * | 2001-06-29 | 2006-05-23 | Genzyme Corporation | Fat-binding polymers |
| US7041280B2 (en) * | 2001-06-29 | 2006-05-09 | Genzyme Corporation | Aryl boronate functionalized polymers for treating obesity |
| US6787558B2 (en) | 2001-09-28 | 2004-09-07 | Hoffmann-La Roche Inc. | Quinoline derivatives |
| GB0202015D0 (en) | 2002-01-29 | 2002-03-13 | Hoffmann La Roche | Piperazine Derivatives |
| PL372295A1 (en) | 2002-02-04 | 2005-07-11 | F.Hoffmann-La Roche Ag | Quinoline derivatives as npy antagonists |
| US20040091450A1 (en) * | 2002-02-26 | 2004-05-13 | The Procter & Gamble Company | Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body |
| BR0308108A (pt) | 2002-02-28 | 2004-12-07 | Hoffmann La Roche | Compostos; processo para a preparação de composto; composição farmacêutica que compreende o mesmo, utilização dos compostos e método de tratamento e profilaxia de enfermidades e de obesidade |
| PL216022B1 (pl) | 2002-04-26 | 2014-02-28 | Hoffmann La Roche | Kompozycja farmaceutyczna, sposób jej wytwarzania i jej zastosowanie, zestaw do leczenia otylosci, inhibitor lipazy w postaci orlistatu i glukomannan lub konjac, zastosowanie inhibitora lipazy w postaci orlistatu oraz zastosowanie glukomannanu lub konjacu |
| CA2489251A1 (fr) | 2002-07-05 | 2004-01-15 | F. Hoffmann-La Roche Ag | Derives de quinazoline |
| AU2003253364B2 (en) | 2002-08-07 | 2007-06-07 | F. Hoffmann-La Roche Ag | Thiazole derivatives |
| ES2209632B1 (es) * | 2002-08-30 | 2005-08-01 | Romildo Holding, N.V. | Complemento dietetico, soluble, efervescente y alimenticio. |
| WO2004024726A1 (fr) | 2002-09-12 | 2004-03-25 | F. Hoffmann-La Roche Ag | Composes d'acide 1h-indol-5-propionique a substitution n en tant qu'agonistes de ppar utiles dans le traitement du diabete |
| DE10248575A1 (de) * | 2002-10-17 | 2004-05-06 | Christian-Albrechts-Universität Zu Kiel | Chiltosanpellets |
| DE60323130D1 (de) | 2002-11-25 | 2008-10-02 | Hoffmann La Roche | Indolderivaten |
| US8372430B2 (en) * | 2002-12-17 | 2013-02-12 | The Procter & Gamble Company | Compositions, methods, and kits useful for the alleviation of gastrointestinal effects |
| GB0310919D0 (en) * | 2003-05-13 | 2003-06-18 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
| GB0314967D0 (en) | 2003-06-26 | 2003-07-30 | Hoffmann La Roche | Piperazine derivatives |
| US20050008699A1 (en) * | 2003-07-11 | 2005-01-13 | Fred Wehling | Effervescent glucosamine composition |
| CN100393718C (zh) | 2003-08-12 | 2008-06-11 | 霍夫曼-拉罗奇有限公司 | 作为npy拮抗剂的噻唑衍生物 |
| CA2533463A1 (fr) | 2003-08-12 | 2005-02-17 | F. Hoffmann-La Roche Ag | Antagonistes 2-amino-5-benzoylthiazole du npy |
| US20080075688A1 (en) * | 2003-10-31 | 2008-03-27 | The Procter & Gamble Company | Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body |
| JP2005154477A (ja) * | 2003-11-20 | 2005-06-16 | Tottori Univ | 紫外線硬化型キトサン誘導体を用いた医療用接着剤および医療用被覆剤 |
| WO2005102292A1 (fr) * | 2004-03-23 | 2005-11-03 | Lytone Enterprise, Inc. | Capsule contenant du chitosane noye ou encapsule |
| US7465417B2 (en) * | 2004-07-19 | 2008-12-16 | Baxter International Inc. | Parametric injection molding system and method |
| MXPA04010692A (es) * | 2004-10-28 | 2006-05-02 | Jorge Luis Rosado Loria | Composicion para el tratamiento de la obesidad e hiperlipidemia. |
| ITMI20050150A1 (it) * | 2005-02-03 | 2006-08-04 | Umberto Cornelli | Prodotti alimentari |
| CA2609634C (fr) | 2005-05-03 | 2011-02-01 | F. Hoffmann-La Roche Ag | Azapyrazinoindolines tetracycliques constituant des ligands 5-ht2 |
| DE602006006712D1 (de) | 2005-08-18 | 2009-06-18 | Hoffmann La Roche | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren |
| ATE507222T1 (de) | 2005-11-30 | 2011-05-15 | Hoffmann La Roche | 1,1-dioxo-thiomorpholinyl-indolyl-methanon- derivate zur verwendung als h3-modulatoren |
| CA2630270A1 (fr) | 2005-11-30 | 2007-06-07 | F. Hoffmann-La Roche Ag | Derives de indole-2-carboxamide substitues en 5 |
| DE602006020482D1 (de) | 2005-11-30 | 2011-04-14 | Hoffmann La Roche | 1,5-substituierte indol-2-yl amidderivative |
| ES2333672T3 (es) | 2005-12-09 | 2010-02-25 | F. Hoffmann-La Roche Ag | Derivados de amida triciclica para tratamiento de obesidad. |
| CN101326187A (zh) | 2005-12-15 | 2008-12-17 | 霍夫曼-拉罗奇有限公司 | 吡咯并[2,3-c]吡啶衍生物 |
| BRPI0619985A2 (pt) | 2005-12-16 | 2011-10-25 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas, métodos para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, de obesidade e de diabetes do tipo ii em um ser humano ou animal e usos dos compostos |
| ITMI20060384A1 (it) * | 2006-03-03 | 2007-09-04 | Umberto Cornelli | Composizioni comprendenti chitosano atte al trattamento terapeutico complessivo o alla prevenzione complessiva della sindrome metabolica |
| KR101252635B1 (ko) * | 2006-04-20 | 2013-04-10 | (주)아모레퍼시픽 | 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제 |
| US7432255B2 (en) | 2006-05-16 | 2008-10-07 | Hoffmann-La Roche Inc. | 1H-indol-5-yl-piperazin-1-yl-methanone derivatives |
| EP2032554A1 (fr) | 2006-05-30 | 2009-03-11 | F. Hoffmann-Roche AG | Dérivés de pipéridinylpyrimidine |
| US7514433B2 (en) | 2006-08-03 | 2009-04-07 | Hoffmann-La Roche Inc. | 1H-indole-6-yl-piperazin-1-yl-methanone derivatives |
| US20080146559A1 (en) | 2006-12-08 | 2008-06-19 | Li Chen | 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives |
| TR200607613A2 (tr) * | 2006-12-29 | 2008-07-21 | NOBEL İLAÇ SAN.ve TiC.A.Ş. | Lipaz inhibitörü içeren farmasötik formülasyonlar |
| EP2016946B1 (fr) * | 2007-07-18 | 2013-02-27 | The Jordanian Pharmaceutical Manufacturing Co. | Composition de coprécipité de chitosane et de dioxyde de silicium pour une utilisation en tant qu'agent thérapeutique |
| WO2009013195A1 (fr) | 2007-07-25 | 2009-01-29 | F. Hoffmann-La Roche Ag | Dérivés d'amide d'acide benzofurane- et benzo[b]thiophène-2-carboxylique et leur utilisation comme modulateurs du récepteur h3 de l'histamine |
| WO2012070702A1 (fr) * | 2010-11-25 | 2012-05-31 | 주식회사 삼양사 | Composition contenant de l'orlistat et du chitosane et son procédé de préparation |
| CN104546768B (zh) * | 2014-12-30 | 2017-06-16 | 重庆植恩药业有限公司 | 含有脂肪酶抑制剂的咀嚼片组合物及其制备方法 |
| CN105520947B (zh) * | 2015-12-24 | 2018-05-01 | 广东药科大学 | 一种含有氨基葡萄糖的具有减肥功能的药物组合物 |
| JOP20180128A1 (ar) * | 2018-12-24 | 2020-06-24 | Univ Of Petra | صيغة دوائية صلبة قابلة للتشتت في الفم |
| GB202212379D0 (en) * | 2022-08-25 | 2022-10-12 | GlaxoSmithKline Consumer Healthcare UK IP Ltd | Novel toothpaste tablet composition |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4223023A (en) * | 1978-10-12 | 1980-09-16 | Ivan Furda | Nonabsorbable lipid binder |
| CA1247547A (fr) * | 1983-06-22 | 1988-12-28 | Paul Hadvary | Derives de leucine |
| US5063210A (en) * | 1989-04-20 | 1991-11-05 | Lange Iii Louis G | Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption |
| CA2098167C (fr) * | 1992-06-24 | 2006-12-19 | Dorothea Isler | Aliments pour humains et animaux contenant un inhibiteur de la lipase |
| PT1105123E (pt) * | 1998-08-14 | 2004-08-31 | Hoffmann La Roche | Composicoes farmaceuticas contendo inibidores da lipase e quitosano |
-
1999
- 1999-08-06 PT PT99940161T patent/PT1105123E/pt unknown
- 1999-08-06 KR KR1020017001803A patent/KR20010079636A/ko not_active Ceased
- 1999-08-06 EP EP99940161A patent/EP1105123B1/fr not_active Expired - Lifetime
- 1999-08-06 WO PCT/EP1999/005693 patent/WO2000009123A1/fr not_active Ceased
- 1999-08-06 JP JP2000564626A patent/JP3761783B2/ja not_active Expired - Lifetime
- 1999-08-06 BR BRPI9912979-5A patent/BR9912979B1/pt not_active IP Right Cessation
- 1999-08-06 ES ES99940161T patent/ES2217797T3/es not_active Expired - Lifetime
- 1999-08-06 DE DE69916288T patent/DE69916288T2/de not_active Expired - Lifetime
- 1999-08-06 CA CA002340052A patent/CA2340052C/fr not_active Expired - Lifetime
- 1999-08-06 AT AT99940161T patent/ATE263558T1/de active
- 1999-08-06 AU AU54205/99A patent/AU759388B2/en not_active Expired
- 1999-08-06 DK DK99940161T patent/DK1105123T3/da active
- 1999-08-06 CN CNB998095087A patent/CN1152680C/zh not_active Expired - Lifetime
- 1999-08-06 TR TR2001/00472T patent/TR200100472T2/xx unknown
- 1999-08-10 US US09/370,845 patent/US6030953A/en not_active Expired - Lifetime
- 1999-08-10 CO CO99050696A patent/CO5160286A1/es unknown
- 1999-08-11 MA MA25726A patent/MA26672A1/fr unknown
- 1999-08-12 PE PE1999000821A patent/PE20000954A1/es not_active Application Discontinuation
- 1999-08-12 AR ARP990104053A patent/AR034691A1/es not_active Application Discontinuation
-
2001
- 2001-01-24 ZA ZA2001/00690A patent/ZA200100690B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010079636A (ko) | 2001-08-22 |
| DK1105123T3 (da) | 2004-08-09 |
| CN1312714A (zh) | 2001-09-12 |
| CA2340052C (fr) | 2007-05-29 |
| BR9912979B1 (pt) | 2010-09-21 |
| ES2217797T3 (es) | 2004-11-01 |
| CA2340052A1 (fr) | 2000-02-24 |
| TR200100472T2 (tr) | 2001-07-23 |
| PT1105123E (pt) | 2004-08-31 |
| WO2000009123A1 (fr) | 2000-02-24 |
| AU759388B2 (en) | 2003-04-10 |
| AU5420599A (en) | 2000-03-06 |
| ZA200100690B (en) | 2002-06-26 |
| JP3761783B2 (ja) | 2006-03-29 |
| DE69916288T2 (de) | 2005-03-24 |
| EP1105123A1 (fr) | 2001-06-13 |
| EP1105123B1 (fr) | 2004-04-07 |
| AR034691A1 (es) | 2004-03-17 |
| US6030953A (en) | 2000-02-29 |
| JP2002522492A (ja) | 2002-07-23 |
| DE69916288D1 (de) | 2004-05-13 |
| CN1152680C (zh) | 2004-06-09 |
| PE20000954A1 (es) | 2000-09-27 |
| CO5160286A1 (es) | 2002-05-30 |
| BR9912979A (pt) | 2001-05-08 |
| ATE263558T1 (de) | 2004-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2340052A1 (fr) | Compositions pharmaceutiques contenant des inhibiteurs de lipases et du chitosane | |
| CA2340056A1 (fr) | Compositions pharmaceutiques comportant des inhibiteurs de lipase | |
| LU91563I2 (fr) | Combinaisson comprenant de l'aliskiren, comme baselibre ou comme un de ses sels pharmaceutiquement acceptables, et de l'hydrochlorothiazide ou un de ses sels pharmaceutiquement acceptables-Rasilez HCT | |
| LU91655I2 (fr) | Corifollitropine alfa et ses dérivés pharmaceutiquement acceptables (ELONVA®) | |
| HUP0201214A3 (en) | Inhibitors of impdh enzyme, pharmaceutical compositions containing them and their use | |
| ES2178157T3 (es) | Tratamiento de arritmias mediante la inhibicion de una proteina quinasa multifuncional dependiente de calcio/calmodulina. | |
| DZ2595A1 (fr) | Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs et procédépour leur préparation. | |
| PL373903A1 (en) | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease | |
| AU7449598A (en) | Medicinal composition for prevention or treatment of hepatopathy | |
| HUP0103575A3 (en) | Inhibitors of caspases, pharmaceutical compositions comprising thereof and their use | |
| DZ2594A1 (fr) | Dérivés de 2-aminopyridine nouveaux et compositions pharmaceutiques les contenant. | |
| LU91122I2 (fr) | Efalizumab et ses dérivés pharmaceutiquement acceptables (raptiva). | |
| BR1100403A (pt) | Composto e composição farmacêutica de inibidores de cox-2 | |
| CA2261040A1 (fr) | Compositions medicinales | |
| BG103425A (en) | Pharmaceutical composition | |
| EP0727217A3 (fr) | Compositions pharmaceutiques et cosmétiques contenant ellagitannin du type god comme principe actif | |
| LU91673I2 (fr) | "Dronédarone et ses dérivés pharmaceutiquement acceptables (MULTAQ)" | |
| CA2348086A1 (fr) | Formulations pharmaceutiques a liberation controlee | |
| PT1177195E (pt) | 1-amino-triazolo¬4,3-a|quinazolina-5-onas e/ou -5-tionas inibidoras de fosfodiesterases iv | |
| PT951473E (pt) | Novos derivados da ciclosporina sua preparacao e composicoes farmaceuticas que os contem | |
| PT97660A (pt) | Processo para a preparacao de composicoes farmaceuticas contendo um agente hipocolesterolizante e um inibidor da enzima de conversao da angiotensina | |
| CA2359354A1 (fr) | Medicament pour le traitement, la prevention et le diagnostic d'une infection due a chlamydia pneumoniae | |
| ID21332A (id) | Metode dan komposisi untuk pengobatan dan pencegahan hiperurikemia | |
| BR9610842A (pt) | Composição farmacêutica compreendendo um inibidor de proteinase e um monoglicerídeo | |
| NO980296L (no) | Forbedrede terapeutiske midler |